Posted: Friday, June 3, 2022
According to research presented at the American Thoracic Society (ATS) 2022 International Conference in San Francisco (Abstract 309), a collaborative partnership between three medical institutions in Philadelphia—Jefferson Health, Penn Medicine, and Temple Health—has characterized lung cancer screening uptake across its community. Using a multidisciplinary approach, the investigators identified major subgroups of participants undergoing lung cancer screening throughout the city, including older residents and those with an extensive history of smoking.
“By bringing together clinical leaders and researchers, the Philadelphia Lung Cancer Learning Community [PLC2] aims to decrease lung cancer morbidity and mortality across the greater Philadelphia region by developing and implementing effective ways to increase [lung cancer screening] and tobacco treatment, particularly in populations at greatest risk,” explained Julie A. Barta, MD, of Thomas Jefferson University, Philadelphia, and colleagues.
The Philadelphia Lung Cancer Learning Community identified 4,429 city residents who underwent lung cancer screening at one of the three member institutions between January 2014 and December 2019. Roughly half (53%) of participants were women, and 46% self-identified as non-Hispanic Black. Almost all participants (99%; n = 4,402) were between the ages of 55 and 79. Most participants (91%; n = 4,011) reported a minimum smoking history of 30 pack-years. A total of 545 participants (12%) experienced positive baseline CT scans.
“Future research is needed to develop common data models, identify geographic areas of need in Philadelphia, and test strategies to increase and improve access to [lung cancer screenings] that can be coordinated across three health systems,” concluded the authors.
Disclosure: For full disclosures of the study authors, visit abstractsonline.com.